Generative AI in Medicine Market Report 2026

The generative AI in medicine market size has grown exponentially in recent years. It will grow from $0.95 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 43.7%. The growth in the historic period can be attributed to advancements in medical imaging technologies, increasing adoption of AI in hospitals and clinics, growth in clinical research initiatives, rising demand for personalized medicine, development of electronic health record (ehr) enhancement tools.

The generative AI in medicine market size is expected to see exponential growth in the next few years. It will grow to $5.77 billion in 2030 at a compound annual growth rate (CAGR) of 43.4%. The growth in the forecast period can be attributed to expansion of AI-assisted drug discovery solutions, integration of generative AI in treatment planning, increased use of virtual nursing assistants, adoption of robot-assisted AI surgery, growth in predictive patient data analytics. Major trends in the forecast period include AI-driven diagnostic tools, personalized treatment planning, virtual nursing assistants, robot-assisted AI surgery, patient data analysis and predictive healthcare.

The surge in digital health records is expected to support the growth of the generative artificial intelligence (AI) in medicine market going forward. Digital health records, also known as electronic health records (EHRs), are organized collections of patient health information stored electronically, enabling data sharing across healthcare environments and improving care quality and efficiency. The increase in digital health records is driven by improvements in patient care, greater efficiency in healthcare delivery, regulatory backing, technological advancements, and enhanced patient engagement. Artificial intelligence (AI) in medicine enhances digital health records by automating documentation, structuring clinical data, generating predictive insights, and creating personalized summaries to improve accuracy, accessibility, and patient outcomes. For example, in July 2024, according to the European Commission, a Belgium-based executive body of the European Union, access to electronic health records increased to 79% in 2024 from 72% in 2023. Therefore, the expansion of digital health records is contributing to the growth of the generative artificial intelligence (AI) in medicine market.

Leading companies operating in the generative artificial intelligence (AI) in medicine market are focused on developing innovative technologies, such as AI solutions for brain health and wellness, to advance cognitive assessment, enhance patient care, and improve mental health management. AI solutions for brain health and wellness are advanced technologies designed to assess, monitor, and support cognitive function and mental well-being. For example, in February 2024, DiagnaMed Holdings Corp., a Canada-based developer of AI-powered digital therapeutics, launched CERVAI, an AI solution dedicated to human mental health and wellness. CERVAI uses advanced algorithms to analyze cognitive tests, brain imaging, and other data inputs, providing personalized assessments and actionable recommendations that support early detection of cognitive issues and targeted interventions.

In December 2024, General Inception, a US-based biotech company igniter, acquired Enable Medicine for an undisclosed amount. Through this acquisition, General Inception aims to advance its generative AI and biological data capabilities by integrating Enable Medicine’s platform, which applies generative AI to search disease-related cellular atlases and uncover novel therapeutic insights. Enable Medicine is a US-based software company specializing in AI-driven generative biological search for drug discovery.

Major companies operating in the generative AI in medicine market are Microsoft Corporation, Intel Corporation, International Business Machines Corporation, NVIDIA Corporation, Philips Healthcare, Veeva Systems Inc., Nuance Communications Inc., Babylon Health Ltd., Tempus Labs Inc., DeepMind Technologies Limited, Owkin Inc., Viz.AI Inc., Recursion Pharmaceuticals Inc., Caresyntax Inc., Relay Therapeutics Inc., Exscientia plc, Paige AI Inc., BenevolentAI Limited, Atomwise Inc., Healx Ltd., Zebra Medical Vision Ltd., Eyenuk Inc., Syntegra Ltd., Arterys Inc.

North America was the largest region in the generative artificial intelligence (AI) in medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative AI in medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generative AI in medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the generative AI in medicine market by increasing the costs of imported AI software platforms, medical imaging devices, and robotic surgery equipment. Regions such as North America, Europe, and Asia-Pacific, which host major hospitals, research institutions, and diagnostic centers, are most affected. The tariffs can lead to higher implementation costs for advanced AI solutions in medical imaging, drug discovery, and robotic surgeries. However, tariffs are also encouraging local innovation in AI medical devices and software development, potentially accelerating regional adoption of generative AI in healthcare.

The generative AI in medicine market research report is one of a series of new reports that provides generative AI in medicine market statistics, including generative AI in medicine industry global market size, regional shares, competitors with a generative AI in medicine market share, detailed generative AI in medicine market segments, market trends and opportunities, and any further data you may need to thrive in the generative AI in medicine industry. This generative AI in medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Generative artificial intelligence (AI) in medicine involves using AI systems to create new data, models, or insights to advance healthcare and medical research. Its goal is to enhance diagnosis, treatment, and overall patient care by leveraging data-driven insights and innovative solutions.

Key components of generative AI in medicine include solutions and services. In this context, solutions refer to the advanced technologies and tools designed to improve healthcare delivery and outcomes. These solutions cover a broad range of applications, such as AI-driven diagnostic tools, virtual nursing assistants, and platforms for medical imaging analysis. Key functions include virtual nursing assistants, robot-assisted AI surgery, administrative process optimization, and medical imaging analysis. Applications span medical imaging, drug discovery, medical diagnosis, patient data analysis, and more. These technologies are utilized by various end-users, including hospitals and clinics, clinical research organizations, healthcare organizations, diagnostic centers, and others.

The generative artificial intelligence (AI) in medicine market consists of revenues earned by entities providing services such as drug discovery and development, clinical trials, diagnostics, and virtual health assistants. The market value includes the value of related goods sold by the service provider or included within the service offering. The generative artificial intelligence (AI) in medicine market also includes medical imaging analysis tools, drug discovery platforms, clinical decision support systems, patient data synthesis solutions, administrative automation software, and precision medicine applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.